Safety and efficacy of the epoetin kappa on anemia and inflammation in hemodialysis patients

Safety and efficacy of the epoetin kappa on anemia and inflammation in hemodialysis patients - EpoKappa study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009253

Enrollment

Registered

2012-11-15

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrogenic anemia patients undergoing hemodialysis

Interventions

Epoetin Kappa (Genetical Recombination)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hemodialysis patients using epoetin alpha or epoetin beta 2. Patients who have given written informed consent to participate in this study (consent of patient himself)

Exclusion criteria

Exclusion criteria: 1. Patients for whom Epoetin Kappa is contraindicated 2. Patient deemed by investigator to be unsuitable for participation in this study

Design outcomes

Primary

Measure	Time frame
Hb concentration,serum erythropoietin level,iron-related indices:serum iron,serum ferritin concentration,IBC(iron binding capacity),TSAT(transferrin saturation),inflammatory markers:PTX3,CRP,TNFa,IL6	—

Countries

Japan

Contacts

Public ContactChieko Hamada

Juntendo University School of Medicine Department of Nephrology

03-5802-1065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026